Jeffrey Minkovitz, MD
Ophthalmology · Wilmington, DENPI 1457358889
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 48.8% of the total. Reporting peaked in 2024 at $2,297 and has fallen 90.8% since, to $212 in 2025. Among ophthalmology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $143.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$3K
- US Oncology Corporate, Inc.$2K
- Alcon$579
- Sun Pharmaceutical Industries Inc.$104
- Johnson & Johnson Surgical Vision, Inc.$103
- Mallinckrodt Hospital Products Inc.$90
- plus $500 from 14 others
Across 4 payments — averaging $2704.25 each. An ownership or investment interest held by the physician or an immediate family member.
- Photonicare Inc$11K
What the payments were for
- Consulting fees$3,30049%
- Travel & lodging$1,36120%
- Food & beverage$2,07431%
- Other$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 3 | $3,300 |
| US Oncology Corporate, Inc. | 3 | $2,080 |
| Alcon | 12 | $579 |
| Sun Pharmaceutical Industries Inc. | 4 | $104 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $103 |
| Mallinckrodt Hospital Products Inc. | 3 | $90 |
| Novartis | 4 | $86 |
| Apellis Pharmaceuticals, Inc. | 2 | $51 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $45 |
| Harrow Eye, LLC | 2 | $44 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Genentech USA, Inc. | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Dompe US, Inc. | 1 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Avedro Inc. | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product in Development$3,300
- Clareon$150
- Catalys Laser System$103
How this compares
$6,757 in reported general payments places this provider in the 95th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $37,327 |
| Prednisolone Acetate | 852 | $27,557 |
| XiidraLifitegrast | 22 | $23,802 |
| LumiganBimatoprost | 18 | $13,013 |
| MoxifloxacinMoxifloxacin Hcl | 521 | $12,017 |
| Restasis MultidoseCyclosporine | 15 | $9,372 |
| Ketorolac Tromethamine | 492 | $8,350 |
| Loteprednol Etabonate | 45 | $7,645 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $5,109 |
| Brimonidine Tartrate | 136 | $4,827 |
| Latanoprost | 438 | $4,745 |
| TobradexTobramycin/Dexamethasone | 11 | $2,860 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 146 | $2,459 |
| Travoprost | 12 | $1,952 |
| Cyclosporine | 14 | $1,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $45 | $7,64545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Wilmington
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Michael BrosmanWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
- Charles WangWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.